Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
State board updates controlled‑substance schedules to match recent DEA, seeks exception for FDA‑approved psilocybin drug
Summary
The State Board of Pharmacy asked the Senate Judiciary Committee to update North Dakota's controlled‑substance schedules to reflect recent DEA actions, add several fentanyl analogues and synthetic compounds, and include a limited exception so an FDA‑approved psilocybin drug could be prescribed.
The North Dakota State Board of Pharmacy asked the Senate Judiciary Committee to update the state's controlled‑substance schedules to reflect recent federal scheduling actions and to add several newly identified fentanyl analogues, synthetic cannabinoids, substituted cathinones and other novel compounds.
Mark Hardy, executive director of the State Board of Pharmacy, told the committee Senate Bill 2064 would bring state law into alignment with federal DEA scheduling actions from the last two years and add a set of synthetic compounds that prosecutors and law‑enforcement labs have encountered. "Our intention in drafting these compounds...is to be as proactive…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
